Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer (Q48252174)

10 February 2018

http://europepmc.org/abstract/MED/20357763

title

Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer (English)

1 reference

10 February 2018

http://europepmc.org/abstract/MED/20357763

0 references

E C Dijkers

1

1 reference

10 February 2018

http://europepmc.org/abstract/MED/20357763

T H Oude Munnink

2

1 reference

10 February 2018

http://europepmc.org/abstract/MED/20357763

J G Kosterink

3

1 reference

10 February 2018

http://europepmc.org/abstract/MED/20357763

A H Brouwers

4

1 reference

10 February 2018

http://europepmc.org/abstract/MED/20357763

P L Jager

5

1 reference

10 February 2018

http://europepmc.org/abstract/MED/20357763

J R de Jong

6

1 reference

10 February 2018

http://europepmc.org/abstract/MED/20357763

G A van Dongen

7

1 reference

10 February 2018

http://europepmc.org/abstract/MED/20357763

C P Schröder

8

1 reference

10 February 2018

http://europepmc.org/abstract/MED/20357763

M N Lub-de Hooge

9

1 reference

10 February 2018

http://europepmc.org/abstract/MED/20357763

E G de Vries

10

1 reference

10 February 2018

http://europepmc.org/abstract/MED/20357763

language of work or name

English

0 references

publication date

31 March 2010

1 reference

10 February 2018

http://europepmc.org/abstract/MED/20357763

published in

Clinical Pharmacology & Therapeutics

1 reference

10 February 2018

http://europepmc.org/abstract/MED/20357763

volume

87

1 reference

10 February 2018

http://europepmc.org/abstract/MED/20357763

issue

5

1 reference

10 February 2018

http://europepmc.org/abstract/MED/20357763

page(s)

586-592

1 reference

10 February 2018

http://europepmc.org/abstract/MED/20357763

cites work

Targeting the HER-kinase axis in cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.12

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.12

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.12

Immunoscintigraphy as potential tool in the clinical evaluation of HER2/neu targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.12

Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.12

Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.12

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.12

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.12

111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.12

Computed Tomography — An Increasing Source of Radiation Exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.12

Brain metastases: the HER2 paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.12

Immuno-PET: a navigator in monoclonal antibody development and applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.12

AMIDE: a free software tool for multimodality medical image analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.12

Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.12

inferred from DOI database lookup

7 January 2021

based on heuristic

Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.12

inferred from DOI database lookup

7 January 2021

based on heuristic

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.12

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2010.12

1 reference

10 February 2018

http://europepmc.org/abstract/MED/20357763

Fatcat ID

release_lea54h5qjfckbnzca6qk4uvoqq

0 references

1 reference

10 February 2018